Merck, Inspirna join forces to develop first-in-class oral cancer inhibitor
Merck, a renowned science and technology company, has reached a significant milestone in its efforts to combat cancer. The company announced a strategic licensing agreement with New York-based Inspirna, Inc. for the development of ompenaclid, a first-in-class oral inhibitor targeting the creatine transport channel SLC6A8, and its follow-on compounds. Ompenaclid, which is currently undergoing a […]